This article was originally published in Start Up
Only 10% of compounds that enter Phase I trials survive to FDA approval, and that has a lot to do with the inadequacy of early-stage research in cell lines. They are poor predictors of what will happen in animal models, much less in patients. The problem stems in part from the fact that cells, once removed from an organism and maintained artificially in a laboratory environment, change their behavior and phenotype in equally artificial ways, which in turn warp their response to drug candidates. HemoShear LLC's technology simulates a cell's natural environment by introducing hemodynamic blood flow and the accompanying shear stresses. Its first system focuses on blood vessels.
You may also be interested in...
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Start-Ups Look For A Place In Coming Hepatitis C Combo Regimens." features profiles of AiCuris, Avila Therapeutics, Okairos, Viroblock and Zirus. Plus these Start-Ups Across Health Care: Arineta, HemoShear, Hygieia and Silver Bullet Therapeutics.
Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.